China Universal Asset Management Co. Ltd. Acquires 627 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

China Universal Asset Management Co. Ltd. grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,590 shares of the company’s stock after purchasing an additional 627 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Medpace were worth $2,189,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Centaurus Financial Inc. increased its stake in shares of Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares in the last quarter. Lindenwold Advisors INC boosted its holdings in Medpace by 1.6% in the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after buying an additional 32 shares during the period. M&T Bank Corp increased its stake in Medpace by 1.2% in the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after buying an additional 37 shares in the last quarter. Custom Index Systems LLC raised its holdings in Medpace by 3.0% during the fourth quarter. Custom Index Systems LLC now owns 1,290 shares of the company’s stock valued at $429,000 after acquiring an additional 37 shares during the period. Finally, Nations Financial Group Inc. IA ADV lifted its position in shares of Medpace by 1.7% in the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock valued at $793,000 after acquiring an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

MEDP has been the subject of several recent analyst reports. TD Cowen dropped their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Redburn Atlantic started coverage on Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 price target for the company. Finally, Truist Financial lowered their target price on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Medpace presently has an average rating of “Hold” and an average target price of $381.44.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $349.15 on Friday. The company has a market cap of $10.85 billion, a P/E ratio of 30.57, a PEG ratio of 1.76 and a beta of 1.36. The firm has a 50-day simple moving average of $342.28 and a two-hundred day simple moving average of $353.35. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.